arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2406.03056stat.MEstat.AP
收藏

个体化治疗的稀疏两阶段贝叶斯元分析

Sparse two-stage Bayesian meta-analysis for individualized treatments

Junwei Shen, Erica E. M. Moodie, Shirin Golchi

AI总结:

针对多中心数据共享受限与双重稀疏性问题,提出两阶段贝叶斯元分析方法估计个体化治疗规则,在保护数据隐私的同时实现参数一致估计,并成功应用于最优华法林剂量策略估计。

摘要:

个体化治疗规则根据临床、人口统计和其他特征为患者量身定制治疗方案。个体化治疗规则的估计需要识别最能从特定治疗中受益的个体,从而检测治疗效果的变异性。由于较小的数据集在检测通常较小的治疗-协变量交互作用时提供的检验效能较低,因此制定有效的个体化治疗规则可能需要多中心研究的数据。然而,个体层面数据的共享有时受到限制。此外,稀疏性可能体现在两个方面:不同的数据中心可能从不同的人群中招募受试者,使得在所有中心估计相同的模型或所有感兴趣的参数变得不可行;并且治疗规则模型中非零参数的数量可能很少。为了解决这些问题,我们采用两阶段贝叶斯元分析方法来估计个体化治疗规则,该方法利用多中心数据优化预期患者结局,同时不向中心外披露个体层面数据。模拟结果表明,我们的方法能够对完全刻画最优个体化治疗规则的参数提供一致估计。我们使用来自 International Warfarin Pharmacogenetics Consortium 的数据估计了最优的华法林剂量策略,其中数据稀疏性和微小的治疗-协变量交互效应带来了额外的统计挑战。

英文摘要:

Individualized treatment rules tailor treatments to patients based on clinical, demographic, and other characteristics. Estimation of individualized treatment rules requires the identification of individuals who benefit most from the particular treatments and thus the detection of variability in treatment effects. To develop an effective individualized treatment rule, data from multisite studies may be required due to the low power provided by smaller datasets for detecting the often small treatment-covariate interactions. However, sharing of individual-level data is sometimes constrained. Furthermore, sparsity may arise in two senses: different data sites may recruit from different populations, making it infeasible to estimate identical models or all parameters of interest at all sites, and the number of non-zero parameters in the model for the treatment rule may be small. To address these issues, we adopt a two-stage Bayesian meta-analysis approach to estimate individualized treatment rules which optimize expected patient outcomes using multisite data without disclosing individual-level data beyond the sites. Simulation results demonstrate that our approach can provide consistent estimates of the parameters which fully characterize the optimal individualized treatment rule. We estimate the optimal Warfarin dose strategy using data from the International Warfarin Pharmacogenetics Consortium, where data sparsity and small treatment-covariate interaction effects pose additional statistical challenges.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑